Levation Pharma, Ltd. received an FDA clearance to initiate Phase I/II of LEV102

The clinical trial is designed to determine preliminary safety and efficacy signals for LEV102 as a potential treatment for Blepharoptosis (prolapse of the upper eyelid in adults). Drooping of the upper eye lid, is a condition that can be both congenital or acquired.